Experimentation Antibubble

The chart shows the growth of an initial investment of $10,000 in Experimentation Antibubble, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced Every 3 months.

Based on dividend-adjusted daily data since Oct 13, 2020, Experimentation Antibubble's average daily return is +0.05%, while the average monthly return is +1.11%. At this rate, an investment would double in approximately 5.2 years.

Historically, 62% of months were positive and 38% were negative. The best month was Nov 2020 with a return of +12.9%, while the worst month was Sep 2022 at -9.2%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 3 months.

On a daily basis, Experimentation Antibubble closed higher 54% of trading days. The best single day was Apr 9, 2025 with a return of +9.2%, while the worst single day was Apr 4, 2025 at -5.8%.

Experimentation Antibubble has an annualized alpha of -0.81%, beta of 1.00, and R2 of 0.95 versus S&P 500 Index. Calculated based on daily prices since October 13, 2020.

• With beta of 1.00 and R2 of 0.95, this portfolio moves broadly in line with S&P 500 Index - much of its variation is explained by market exposure rather than independent behavior.

Experimentation Antibubble has an expense ratio of 0.06%, which is considered low. Below, you can find the expense ratios of the portfolio's funds side by side and easily compare their relative costs.

Experimentation Antibubble ranks 48 for risk / return — on par with similar Portfolios. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

The current Experimentation Antibubble Sharpe ratio is 2.03 as of Jun 11, 2026 (the value is recalculated daily), calculated over the past 12 months.

Compared to the broad market, where average Sharpe ratios range from 1.45 to 2.28, this portfolio's current Sharpe ratio falls between the 25th and 75th percentiles. This indicates that its risk-adjusted performance is in line with the majority of portfolios, suggesting a balanced approach to risk and return—likely suitable for a wide range of investors.

The chart below shows the rolling Sharpe ratio of Experimentation Antibubble compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.

Experimentation Antibubble provided a 1.10% dividend yield over the last twelve months.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Experimentation Antibubble. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Experimentation Antibubble was 27.07%, occurring on Oct 14, 2022. Recovery took 339 trading sessions.

The current Experimentation Antibubble drawdown is 4.02%.

The chart below shows the rolling one-month volatility.